Selected research
Industry Research
Recombinant Coagulation Factor Ⅷ for Injection Industry Research Report 2026
Market perspective
The global Recombinant Coagulation Factor Ⅷ for Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Recombinant Coagulation Factor Ⅷ for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Recombinant Coagulation Factor Ⅷ for Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Recombinant Coagulation Factor Ⅷ for Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Recombinant Coagulation Factor Ⅷ for Injection include GC Pharma, Novo Nordisk A/S, SinoCell Tech, Baxter, Bayer, Hualan Biological, Pfizer, Shanghai Raas Corp and Shanghai Xinxing Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Recombinant Coagulation Factor Ⅷ for Injection market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Coagulation Factor Ⅷ for Injection Market by Company
GC Pharma
Novo Nordisk A/S
SinoCell Tech
Baxter
Bayer
Hualan Biological
Pfizer
Shanghai Raas Corp
Shanghai Xinxing Medicine
Shandong Taibang Biological Products
Recombinant Coagulation Factor Ⅷ for Injection Segment by Type
250 IU/Bottle
500 IU/Bottle
1000 IU/Bottle
2000 IU/Bottle
Recombinant Coagulation Factor Ⅷ for Injection Segment by Application
Hospital
Clinic
Others
Recombinant Coagulation Factor Ⅷ for Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Coagulation Factor Ⅷ for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Coagulation Factor Ⅷ for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Coagulation Factor Ⅷ for Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Coagulation Factor Ⅷ for Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Coagulation Factor Ⅷ for Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Coagulation Factor Ⅷ for Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 250 IU/Bottle
- 500 IU/Bottle
- 1000 IU/Bottle
- 2000 IU/Bottle
Applications
- Hospital
- Clinic
- Others
Companies covered
- GC Pharma
- Novo Nordisk A/S
- SinoCell Tech
- Baxter
- Bayer
- Hualan Biological
- Pfizer
- Shanghai Raas Corp
- Shanghai Xinxing Medicine
- Shandong Taibang Biological Products
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size (2021-2032)
- 2.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales (2021-2032)
- 2.2.3 Global Recombinant Coagulation Factor Ⅷ for Injection Market Average Price (2021-2032)
- 2.3 Recombinant Coagulation Factor Ⅷ for Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 250 IU/Bottle
- 2.3.3 500 IU/Bottle
- 2.3.4 1000 IU/Bottle
- 2.3.5 2000 IU/Bottle
- 2.4 Recombinant Coagulation Factor Ⅷ for Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Recombinant Coagulation Factor Ⅷ for Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Recombinant Coagulation Factor Ⅷ for Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Recombinant Coagulation Factor Ⅷ for Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Recombinant Coagulation Factor Ⅷ for Injection, Product Type & Application
- 3.8 Global Manufacturers of Recombinant Coagulation Factor Ⅷ for Injection, Established Date
- 3.9 Global Recombinant Coagulation Factor Ⅷ for Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GC Pharma
- 4.1.1 GC Pharma Company Information
- 4.1.2 GC Pharma Business Overview
- 4.1.3 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GC Pharma Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.1.5 GC Pharma Recent Developments
- 4.2 Novo Nordisk A/S
- 4.2.1 Novo Nordisk A/S Company Information
- 4.2.2 Novo Nordisk A/S Business Overview
- 4.2.3 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novo Nordisk A/S Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.2.5 Novo Nordisk A/S Recent Developments
- 4.3 SinoCell Tech
- 4.3.1 SinoCell Tech Company Information
- 4.3.2 SinoCell Tech Business Overview
- 4.3.3 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 SinoCell Tech Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.3.5 SinoCell Tech Recent Developments
- 4.4 Baxter
- 4.4.1 Baxter Company Information
- 4.4.2 Baxter Business Overview
- 4.4.3 Baxter Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Baxter Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.4.5 Baxter Recent Developments
- 4.5 Bayer
- 4.5.1 Bayer Company Information
- 4.5.2 Bayer Business Overview
- 4.5.3 Bayer Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bayer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.5.5 Bayer Recent Developments
- 4.6 Hualan Biological
- 4.6.1 Hualan Biological Company Information
- 4.6.2 Hualan Biological Business Overview
- 4.6.3 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hualan Biological Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.6.5 Hualan Biological Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Shanghai Raas Corp
- 4.8.1 Shanghai Raas Corp Company Information
- 4.8.2 Shanghai Raas Corp Business Overview
- 4.8.3 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Shanghai Raas Corp Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.8.5 Shanghai Raas Corp Recent Developments
- 4.9 Shanghai Xinxing Medicine
- 4.9.1 Shanghai Xinxing Medicine Company Information
- 4.9.2 Shanghai Xinxing Medicine Business Overview
- 4.9.3 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Shanghai Xinxing Medicine Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.9.5 Shanghai Xinxing Medicine Recent Developments
- 4.10 Shandong Taibang Biological Products
- 4.10.1 Shandong Taibang Biological Products Company Information
- 4.10.2 Shandong Taibang Biological Products Business Overview
- 4.10.3 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Shandong Taibang Biological Products Recombinant Coagulation Factor Ⅷ for Injection Product Portfolio
- 4.10.5 Shandong Taibang Biological Products Recent Developments
5 Global Recombinant Coagulation Factor Ⅷ for Injection Market Scenario by Region
- 5.1 Global Recombinant Coagulation Factor Ⅷ for Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021-2032
- 5.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2021-2026
- 5.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Region: 2027-2032
- 5.3 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region: 2021-2032
- 5.3.1 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region: 2021-2026
- 5.3.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Region: 2027-2032
- 5.4 North America Recombinant Coagulation Factor Ⅷ for Injection Market Facts & Figures by Country
- 5.4.1 North America Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
- 5.4.3 North America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Recombinant Coagulation Factor Ⅷ for Injection Market Facts & Figures by Country
- 5.5.1 Europe Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
- 5.5.3 Europe Recombinant Coagulation Factor Ⅷ for Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Recombinant Coagulation Factor Ⅷ for Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Recombinant Coagulation Factor Ⅷ for Injection Market Facts & Figures by Country
- 5.7.1 South America Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
- 5.7.3 South America Recombinant Coagulation Factor Ⅷ for Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Recombinant Coagulation Factor Ⅷ for Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032)
- 6.1.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Type (2021-2032)
- 6.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Recombinant Coagulation Factor Ⅷ for Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032)
- 7.1.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Recombinant Coagulation Factor Ⅷ for Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue by Application (2021-2032)
- 7.2.1 Global Recombinant Coagulation Factor Ⅷ for Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Recombinant Coagulation Factor Ⅷ for Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Recombinant Coagulation Factor Ⅷ for Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Recombinant Coagulation Factor Ⅷ for Injection Value Chain Analysis
- 8.1.1 Recombinant Coagulation Factor Ⅷ for Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Recombinant Coagulation Factor Ⅷ for Injection Production Mode & Process
- 8.2 Recombinant Coagulation Factor Ⅷ for Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Recombinant Coagulation Factor Ⅷ for Injection Distributors
- 8.2.3 Recombinant Coagulation Factor Ⅷ for Injection Customers
9 Global Recombinant Coagulation Factor Ⅷ for Injection Analyzing Market Dynamics
- 9.1 Recombinant Coagulation Factor Ⅷ for Injection Industry Trends
- 9.2 Recombinant Coagulation Factor Ⅷ for Injection Industry Drivers
- 9.3 Recombinant Coagulation Factor Ⅷ for Injection Industry Opportunities and Challenges
- 9.4 Recombinant Coagulation Factor Ⅷ for Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst